贸易 来源:界面新闻 时间:2023-06-09 07:22:45
(资料图)
贝达药业6月8日公告,今日,国家药监局官方网站公示,国家药监局批准公司申报的1类创新药伏罗尼布片上市。
伏罗尼布是具有全新化学结构的新一代多靶点酪氨酸激酶血管内皮生长因子受体(VEGFR)/ 血小板衍化生长因子受体(PDGFR)抑制剂,可抑制肿瘤血管生成及生长,可用于治疗病理性血管生成性疾病。
标签:
下一篇:最后一页
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-08
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
22-09-30
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09
23-06-09